论文部分内容阅读
目的观察瑞巴派特保留灌肠联合5-氨基水杨酸口服对溃疡性结肠炎的疗效。方法128例患者随机分为瑞巴派特治疗组、思密达治疗组和对照组。瑞巴派特治疗组应用瑞巴派特保留灌肠联合5-氨基水杨酸口服治疗,思密达治疗组应用思密达保留灌肠联合5-氨基水杨酸口服治疗,对照组采用5-氨基水杨酸口服治疗。结果瑞巴派特灌肠治疗组总有效率90.69%,明显高于思密达治疗组(总有效率82.5%)及对照组(总有效率68.88%,P<0.05)。结论瑞巴派特保留灌肠联合5-氨基水杨酸口服对溃疡性结肠炎的疗效优于思密达灌肠治疗及传统治疗。
Objective To observe the effect of rebamipide enema combined with 5-aminosalicylic acid on ulcerative colitis. Methods 128 patients were randomly divided into rebamipide treatment group, Smecta treatment group and control group. Rebamipide treatment group treated with rebamipide retention enema combined with 5-aminosalicylic acid oral treatment, the Smectite treatment group with Smecta retention enema combined with 5-amino salicylic acid oral treatment, the control group with 5-amino Salicylic acid oral treatment. Results Rebamip enema treatment group total effective rate 90.69%, significantly higher than the Smectite treatment group (total effective rate 82.5%) and the control group (total effective rate 68.88%, P <0.05). Conclusion The efficacy of rebamipide enema combined with 5-aminosalicylic acid orally on ulcerative colitis is better than that of Smecta enema and traditional treatment.